More documents

Recommendations

Info

Гласник интелектуалне својине 2012/5Intellectual Property Gazette 2012/5A(51)Broj objave evropskeprijave patentaA 61P 25/14 EP 2484363 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamideA 61P 25/16 EP 2483254 * NOVEL COMPOUNDSA 61P 25/16 EP 2484363 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamideA 61P 25/18 EP 2484363 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamideA 61P 25/20 EP 2392572 Substituted diazepan compounds as orexin receptor antagonistsA 61P 25/22 EP 2484363 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamideA 61P 25/24 EP 2477626 * ROLE OF N-2 HYDROXY-ETHYL-PIPERAZINE-N'-2-ETHANE SULFONIC ACID (HEPES) IN PAIN CONTROLAND REVERSAL OF DEMYELINIZATION INJURYA 61P 25/24 EP 2484363 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamideA 61P 25/28 EP 2127651 STABILIZED MEDICINAL COMPOSITION CONTAININGDONEPEZIL, METHOD OF PRODUCING THE SAME ANDMETHOD FOR STABILIZATIONA 61P 25/28 EP 2402002 Compositions of an orally active 1,2,4-oxadiazole for nonsensemutation suppression therapyA 61P 25/28 EP 2475428 * HETEROCYLCIC DERIVATIVES AS INHIBITORS OFGLUTAMINYL CYCLASEA 61P 25/28 EP 2483254 * NOVEL COMPOUNDSA 61P 25/28 EP 2484363 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamideA 61P 25/28 EP 2494976 Methods for the treatment of a traumatic central nervous systeminjuryA 61P 25/30 EP 2477626 * ROLE OF N-2 HYDROXY-ETHYL-PIPERAZINE-N'-2-ETHANE SULFONIC ACID (HEPES) IN PAIN CONTROLAND REVERSAL OF DEMYELINIZATION INJURYA 61P 27/02 EP 2056804 * USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FORTHE TREATMENT OF OCULAR DISEASESA 61P 27/02 EP 2480249 * USE OF PLASMIN FOR THE TREATMENT OF FILTRATIONFAILURE AFTER TRABECULECTOMYA 61P 27/02 EP 2481738 MALEIC ACID SALT AND CRYSTAL THEREOFA 61P 29/00 EP 2399585 Boronic acids and esters as inhibitors of fatty acid amide hydrolaseA 61P 29/00 EP 2404607 Boronic acids and esters as inhibitors of fatty acid amide hydrolaseA 61P 29/00 EP 2477625 * PHARMACEUTICAL COMPOSITIONS ANDFORMULATIONS INCLUDING INHIBITORS OF THEPLECKSTRIN HOMOLOGY DOMAIN AND METHODS FORUSING SAMEA 61P 29/00 EP 2480232 * DISUBSTITUTED ]4-(5-AMINOMETHYL-PHENYL)-PIPERIDIN-1-YL]-1H-INDOL-3-YL]-METHANONESA 61P 29/00 EP 2480531 * PYRROLIDINONE CARBOXAMIDE DERIVATIVES ASCHEMERIN-R ( CHEMR23 ) MODULATORSA 61P 29/00 EP 2480547 * INDOLIZINE INHIBITORS OF 5-LIPOXYGENASEA 61P 29/00 EP 2480548 * INDOLIZINE INHIBITORS OF 5-LIPOXYGENASEA 61P 29/00 EP 2481738 MALEIC ACID SALT AND CRYSTAL THEREOFA 61P 29/00 EP 2482850 * TOPICAL FORMULATIONSA 61P 29/00 EP 2484363 (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamideA 61P 31/04 EP 2476701 ANTIMICROBIAL AGENTS BASED ON HEMINDERIVATIVESA 61P 31/04 EP 2477989 * COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITYA 61P 31/04 EP 2481738 MALEIC ACID SALT AND CRYSTAL THEREOFA 61P 31/04 EP 2484696 Antagonistic human light-specific human monoclonal antibodiesA 61P 31/10 EP 2409706 Dihydropteridinones for the treatment of cancer diseasesA 61P 31/10 EP 2476701 ANTIMICROBIAL AGENTS BASED ON HEMINDERIVATIVESA 61P 31/12 EP 2475657 * INHIBITORS OF FLAVIVIRIDAE VIRUSES(54)ЗИС / RS / IPO 2747
Гласник интелектуалне својине 2012/5A Intellectual Property Gazette 2012/5(51)Broj objave evropskeprijave patentaA 61P 31/12 EP 2476440 THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OFHPV-INDUCED DISEASESA 61P 31/12 EP 2484696 Antagonistic human light-specific human monoclonal antibodiesA 61P 31/18 EP 2480220 * TREATMENT AND PREVENTION OF HIV INFECTIONA 61P 33/00 EP 2475430 * GRANULATED ANTHELMINTIC PREPARATIONS ANDDELIVERY SYSTEMSA 61P 35/00 EP 2061453 * 2,5-DIHYDROXYBENZENE COMPOUNDS FOR TREATINGCANCERS AND HEMATOLOGICAL DYSCRASIASA 61P 35/00 EP 2074114 * PYRIMIDINONES AS CASEIN KINASE II (CK2)MODULATORSA 61P 35/00 EP 2074148 * NOVEL ANTIPROLIFERATION ANTIBODIESA 61P 35/00 EP 2078003 * ANILINOPIPERAZINE DERIVATIVES AND METHODS OFUSE THEREOFA 61P 35/00 EP 2079746 * IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORSA 61P 35/00 EP 2114950 * PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDSAND METHODS OF USEA 61P 35/00 EP 2119707 COMPOSITION FOR TREATMENT OFUNDIFFERENTIATED-TYPE OF GASTRIC CANCERA 61P 35/00 EP 2121590 * COMPOUNDS HAVING ARYL-SULPHONAMIDICSTRUCTURE USEFUL AS METALLOPROTEASESINHIBITORSA 61P 35/00 EP 2325180 Chiral CIS-imidazolinesA 61P 35/00 EP 2380879 Tetrahydroindolone and tetrahydroindazolone derivativesA 61P 35/00 EP 2392337 Use of 24-norUDCAA 61P 35/00 EP 2395000 Benzimidazole compounds that modulate the activity of CDK,GSK and aurora kinasesA 61P 35/00 EP 2397138 Method of inhibiting C-KIT kinaseA 61P 35/00 EP 2399605 Extending time to disease progression or survival in cancerpatientsA 61P 35/00 EP 2402002 Compositions of an orally active 1,2,4-oxadiazole for nonsensemutation suppression therapyA 61P 35/00 EP 2402334 Inhibitors of E1 Activating EnzymesA 61P 35/00 EP 2409700 Methods of treatment using intravenous formulations comprisingtemozolomideA 61P 35/00 EP 2409706 Dihydropteridinones for the treatment of cancer diseasesA 61P 35/00 EP 2415784 Novel antibodies inhibiting C-Met dimerization, and uses thereofA 61P 35/00 EP 2417974 Combination therapy for treatment of immune disordersA 61P 35/00 EP 2475368 * N-4 ( - ( ( 3- ( 2 -AMINO-4 PYRIMIDINYL) -2 -PYRIDINYL)OXY) PHENYL) -4- (4-METHYL-2-THIENYL) -1-PHTHALAZINAMINE FOR USE IN THE TREATMENT OFANTIMITOTIC AGENT RESISTANT CANCERA 61P 35/00 EP 2475648 * ORTHO SUBSTITUTED PYRIMIDINE COMPOUNDS AS JAKINHIBITORSA 61P 35/00 EP 2475653 * SUSTITUTED ( HETEROARYLMETHYL )THIOHYDANTOINS AS ANTICANCER DRUGSA 61P 35/00 EP 2476440 THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OFHPV-INDUCED DISEASESA 61P 35/00 EP 2477625 * PHARMACEUTICAL COMPOSITIONS ANDFORMULATIONS INCLUDING INHIBITORS OF THEPLECKSTRIN HOMOLOGY DOMAIN AND METHODS FORUSING SAMEA 61P 35/00 EP 2477653 * DOSAGE REGIMEN FOR ADMINISTERING ANEPCAMXCD3 BISPECIFIC ANTIBODYA 61P 35/00 EP 2477655 * VACCINES DIRECTED TO LANGERHANS CELLSA 61P 35/00 EP 2477989 * COMPOUNDS HAVING TAFIa INHIBITORY ACTIVITYA 61P 35/00 EP 2480668 * COMPOSITIONS AND METHODS FOR SILENCING GENESEXPRESSED IN CANCERA 61P 35/00 EP 2483271 * PYRAZOLINE DIONE DERIVATIVES AS NADPH OXIDASEINHIBITORSA 61P 35/00 EP 2483277 * BENZOXEPIN PI3K INHIBITOR COMPOUNDS ANDMETHODS OF USE(54)2748 ЗИС / RS / IPO
Page 2:
Гласникинтелектуа
Page 6 and 7:
Гласник интелектуа
Page 8 and 9:
Page 10 and 11:
Page 12 and 13:
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
Page 22 and 23:
Page 24 and 25:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Page 83 and 84:
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209: Гласник интелектуа
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
Page 386 and 387:
Page 388 and 389:
Page 390 and 391:
Page 392 and 393:
Page 394 and 395:
Page 396 and 397:
Page 398 and 399:
Page 400 and 401:
Page 402 and 403:
Page 404 and 405:
Page 406 and 407:
Page 408 and 409:
Page 410 and 411:
Page 412 and 413:
Page 414 and 415:
Page 416 and 417:
Page 418 and 419:
Page 420 and 421:
Page 422 and 423:
Page 424 and 425:
Page 426 and 427:
Page 428 and 429:
Page 430 and 431:
Page 432 and 433:
Page 434 and 435:
Page 436 and 437:
Page 438 and 439:
Page 440 and 441:
Page 442 and 443:
Page 444 and 445:
Page 446 and 447:
Page 448 and 449:
Page 450 and 451:
Page 452 and 453:
Page 454 and 455:
Page 456 and 457:
Page 458 and 459:
Page 460 and 461:
Page 462 and 463:
Page 464 and 465:
Page 466 and 467:
Page 468 and 469:
Page 470 and 471:
Page 472 and 473:
Page 474 and 475:
Page 476 and 477:
Page 478 and 479:
Page 480 and 481:
Page 482 and 483:
Page 484 and 485:
Page 486 and 487:
Page 488 and 489:
Page 490 and 491:
Page 492 and 493:
Page 494 and 495:
Page 496 and 497:
Page 498 and 499:
Page 500 and 501:
Page 502 and 503:
Page 504 and 505:
Page 506 and 507:
Page 508 and 509:
Page 510 and 511:
Page 512 and 513:
Page 514 and 515:
Page 516 and 517:
Page 518 and 519:
Page 520 and 521:
Page 522 and 523:
Page 524 and 525:
Page 526 and 527:
Page 528 and 529:
Page 530 and 531:
Page 532 and 533:
Page 534 and 535:
Page 536 and 537:
Page 538 and 539:
Page 540 and 541:
Page 542 and 543:
Page 544 and 545:
Page 546 and 547:
Page 548 and 549:
Page 550 and 551:
Page 552 and 553:
Page 554 and 555:
Page 556 and 557:
Page 558 and 559:
Page 560 and 561:
Page 562 and 563:
Page 564 and 565:
Page 566 and 567:
Page 568 and 569:
Page 570 and 571:
Page 572 and 573:
Page 574 and 575:
Page 576 and 577:
Page 578 and 579:
Page 580 and 581:
Page 582:
Page 586 and 587:
Подлистак ГИС 2012/5Sup
Page 588 and 589:
Page 590 and 591:
Page 592 and 593:
Page 594 and 595:
Page 596:
Page 599:
ГЛАСНИК ИНТЕЛЕКТУА
show all

ÐÐ»Ð°ÑÐ½Ð¸Ðº Ð¸Ð½ÑÐµÐ»ÐµÐºÑÑÐ°Ð»Ð½Ðµ ÑÐ²Ð¾ÑÐ¸Ð½Ðµ 2012/05 - ÐÐ°Ð²Ð¾Ð´ Ð·Ð° ...

Create successful ePaper yourself

Delete template?

Save as template?

ÐÐ»Ð°ÑÐ½Ð¸Ðº Ð¸Ð½ÑÐµÐ»ÐµÐºÑÑÐ°Ð»Ð½Ðµ ÑÐ²Ð¾ÑÐ¸Ð½Ðµ 2012/05 - ÐÐ°Ð²Ð¾Ð´ Ð·Ð° ...